NCT05785377View on ClinicalTrials.gov

Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia

NANot yet recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 1, 2027

Conditions
Analgesia
Interventions
DRUG

Bupivacaine-Neostigmine

20 mL bupivacaine 0.25% plus 1 mL Neostigmine (500 mcg)

DRUG

Bupivacaine

20 mL bupivacaine 0.25% plus 1 mL normal saline 0.9%

Trial Locations (1)

35511

Mansoura University-Emergency hospital-ICU, El Mansoura

All Listed Sponsors
lead

Mansoura University

OTHER

NCT05785377 - Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia | Biotech Hunter | Biotech Hunter